NCT00082810View on ClinicalTrials.gov

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

July 31, 2008

Study Completion Date

September 30, 2008

Conditions
Estrogen Receptor-positive Breast CancerRecurrent Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

fulvestrant

Given intramuscularly

DRUG

tipifarnib

Given IV

Trial Locations (1)

10467-2490

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00082810 - Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter